New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients
The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A […]
